An observational study in Osteoarthritis, Foot Osteoarthritis and Joint Diseases, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Assiut University · Observational
This cross-sectional study aims to assess the diagnostic accuracy of triphasic bone scintigraphy and SPECT/CT in evaluating foot and ankle osteoarthritis, using magnetic resonance imaging (MRI) as the reference standard, and to determine the affected joints.
Osteoarthritis of the foot and ankle is a significant cause of chronic pain and functional impairment. Conventional radiography has limited sensitivity for early changes, while magnetic resonance imaging (MRI) is considered the reference standard for evaluating cartilage, bone marrow edema, and soft tissue structures.
Nuclear medicine techniques provide functional information about bone metabolism. Triphasic bone scan using technetium-99m methylene diphosphonate (99mTc-MDP) assesses perfusion, blood pool, and delayed skeletal uptake. However, planar imaging has limited spatial resolution and anatomical localization in the complex anatomy of the foot and ankle.
Hybrid SPECT/CT combines the functional data of SPECT with the precise anatomical localization of CT, improving diagnostic confidence and specificity. This study will evaluate the diagnostic accuracy of triphasic bone scan and SPECT/CT compared with MRI in patients with suspected foot and ankle osteoarthritis.
2,974 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
This study's planned enrollment of 40 is below the median of 100 across 601 observational studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients with chronic foot and/or ankle pain suspected of osteoarthritis referred to the Nuclear Medicine Unit at Assiut University Hospital who meet the eligibility criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age ≥ 18 years
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic accuracy of triphasic bone scan and SPECT/CT
Sensitivity, specificity, positive predictive value, and negative predictive value of triphasic bone scintigraphy and SPECT/CT for detecting foot and ankle osteoarthritis, using MRI as the reference standard.
Time frame: Baseline
Identification of affected joints
Determination of the specific joints affected by osteoarthritis in the foot and ankle based on SPECT/CT and MRI findings.
Time frame: Baseline
No study locations are listed for this record.
Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.